DC-based cancer vaccines.

By Eli Gilboa. Journal of Clinical Investigation, 2007

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Immune evasion in cancer: Mechanistic basis and therapeutic strategies. (2015, background): “Myeloid cells, especially 163 “myeloid-derived suppressor cells” (MDSCs), modulated dendritic cells (DCs) and alternatively-164 activated M1 and M2 macrophages create an inflammatory microenvironment and can also ct as 165 mediators of tumor initiation, angiogenesis, and metastasis [23,24].”
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008, background): “Diverse vaccination strategies, however, may enhance the acquisition and processing of tumor antigens by dendritic cells and thereby engender protective immunity (3).”